MOMENTUM: Pemvidutide Phase 2 obesity trial
Mean loss 10.3%, 11.2%, 15.6% vs 2.2% placebo; at 2.4 mg, 51.8% achieved ≥15% and 32.1% ≥20% weight loss.
What this study tells us
Participants were assigned to comparison groups by chance, usually with placebo and/or blinding to reduce bias. This is a strong design for testing cause and effect, but the population, duration and endpoints still limit what can be concluded.
Adults with obesity or overweight plus ≥1 obesity-related comorbidity
n=391
Mean loss 10.3%, 11.2%, 15.6% vs 2.2% placebo; at 2.4 mg, 51.8% achieved ≥15% and 32.1% ≥20% weight loss.
Conference abstract rather than full peer-reviewed article; weight-loss programme later shifted strategic emphasis toward liver disease.
Need help with terms such as randomized, placebo, endpoint or sample size? Open the glossary →
Key result
Mean loss 10.3%, 11.2%, 15.6% vs 2.2% placebo; at 2.4 mg, 51.8% achieved ≥15% and 32.1% ≥20% weight loss.